Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...

Eli Lilly has been a terrific stock to own for the past five years, thanks to its excellent clinical and regulatory progress. The company's breakthroughs are paying off. In each of the past six ...

Duchenne muscular dystrophy (DMD) is the most common type. It’s caused by flaws in the gene that controls how ... Scientists continue to look for new ways to treat DMD in clinical trials.

As we can see below, Elevidys looks set to become the most successful gene therapy launch ... a field of drug development as tricky as DMD. If you like what you have just read and want to receive ...

Sarepta is pressing forward with a bold plan to file with the FDA for accelerated approval of its gene therapy SRP-9001 for Duchenne muscular dystrophy ... "We look forward to a collaborative ...

However, before going over this entire program plus any catalysts that investors should look forward ... advancing two other gene therapy candidates, which are SGT-003 for DMD and SGT-501 for ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Cutting-Edge Cardiac Research: Novoheart’s CTScreen™ system has been installed at UMC Utrecht, equipping Regenerative Medicine Center with advanced high-throughput tools to accelerate human cardiac ...

We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to ...

“Just a week before Christmas, we were told Archie had Duchenne Muscular Dystrophy ... said Archie is eligible for gene therapy in the hospital. Unfortunately, the cost is an astronomical €3.2m. They ...